Variation in Care of Inflammatory Bowel Diseases Patients in Crohn's and Colitis Foundation of America Partners: Role of Gastroenterologist Practice Setting in Disease Outcomes and Quality Process Measures

被引:26
|
作者
Weaver, Kimberly N. [1 ]
Kappelman, Michael D. [2 ,3 ]
Sandler, Robert S. [3 ,4 ]
Martin, Christopher F. [3 ,4 ]
Chen, Wenli [3 ,4 ]
Anton, Kristen [4 ,5 ]
Long, Millie D. [3 ,4 ]
机构
[1] Univ North Carolina Chapel Hill, Dept Med, Chapel Hill, NC USA
[2] Univ North Carolina Chapel Hill, Div Pediat Gastroenterol & Hepatol, Chapel Hill, NC USA
[3] Univ North Carolina Chapel Hill, Ctr Gastrointestinal Biol & Dis, Chapel Hill, NC USA
[4] Univ North Carolina Chapel Hill, Div Gastroenterol & Hepatol, Chapel Hill, NC USA
[5] Geisel Sch Med Dartmouth, Hanover, NH USA
关键词
ULCERATIVE-COLITIS; ACTIVITY INDEX; OF-CARE; VALIDATION; HOSPITALS; EXPERTS; LIFE;
D O I
10.1097/MIB.0000000000000933
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background:As variation in care has previously been linked to quality, we aimed to describe variations in inflammatory bowel diseases care by gastroenterology (GI) practice setting.Methods:We performed a cross-sectional study within the Crohn's and Colitis Foundation of America Partners and used bivariate analyses to compare patient characteristics by GI practice setting (GI-academic [GIA], GI-private, or GI-other). Regression models were used to describe the effects of provider type on steroid use, disease activity, and the quality of life.Results:The study included 12,083 patients with inflammatory bowel diseases (7576 with Crohn's disease [CD] and 4507 with ulcerative colitis [UC]). Nearly 95% reported visiting a GI provider annually. Also, CD patients seen by GIA were younger, better educated, used less 5-aminosalicylate agents, and had higher biologic and immunomodulator use (P < 0.001 for all). On multivariate analysis of CD patients, GIA used less steroids when compared with GI-private (odds ratio, 0.84; 95% confidence interval, 0.67-1.06) or GI-other (odds ratio, 0.66; 95% confidence interval, 0.49-0.89). GIA patients were more likely to be in remission, have flu vaccine, and have better quality of life. UC patients seen by GIA were younger, had more hospitalizations, and previous surgery (P < 0.001 for all). No differences existed for steroid use, remission, flu vaccine, or quality of life for UC care on bivariate or multivariate analyses.Conclusions:Significant variations in care patterns and quality measures exist for CD across GI provider types, without similar variation in UC care. Interventions to reduce variations in care could improve the quality of care in CD.
引用
收藏
页码:2672 / 2677
页数:6
相关论文
共 39 条
  • [31]  The evolving role of technology in delivering patient-centric care in inflammatory bowel disease - an australasian experience using crohn's colitis care e-health patient portal
    McNamara, Jack
    Pipicella, Joseph Louis
    Connor, Susan Jane
    Andrews, Jane Mary
    GUT, 2023, 72 (SUPPL_1) : A203 - A203
  • [32] Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn's disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource
    Stournaras, Evangelos
    Qian, Wendi
    Pappas, Apostolos
    Hong, You Yi
    Shawky, Rasha
    Raine, Tim
    Parkes, Miles
    GUT, 2021, 70 (04) : 677 - 686
  • [33] INSPIRE Study: Does Stress Management Improve the Course of Inflammatory Bowel Disease and Disease-specific Quality of Life in Distressed Patients with Ulcerative Colitis or Crohn's Disease? A Randomized Controlled Trial
    Boye, Birgitte
    Lundin, Knut E. A.
    Jantschek, Guenter
    Leganger, Siv
    Mokleby, Kjell
    Tangen, Tone
    Jantschek, Ingrid
    Pripp, Are H.
    Wojniusz, Swavek
    Dahlstroem, Astri
    Rivenes, Ann Christin
    Benninghoven, Dieter
    Hausken, Trygve
    Roseth, Arne
    Kunzendorf, Sebastian
    Wilhelmsen, Ingvard
    Sharpe, Michael
    Blomhoff, Svein
    Malt, Ulrik F.
    Jahnsen, Jorgen
    INFLAMMATORY BOWEL DISEASES, 2011, 17 (09) : 1863 - 1873
  • [34] Quality of care in inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 2nd Asian Organization of Crohn's and Colitis (AOCC) meeting in Seoul
    Song, Hye Kyung
    Lee, Kang-Moon
    Jung, Sung-Ae
    Hong, Sung Noh
    Han, Dong Soo
    Yang, Suk-Kyun
    INTESTINAL RESEARCH, 2016, 14 (03) : 240 - 247
  • [35] The Evolving Role of Technology in Delivering Patient-centric, Empowered Health Care in Inflammatory Bowel Disease: Patient Experience Using Crohn's Colitis Care e-Health Consumer Platform
    McNamara, Jack
    Connor, Susan J.
    Andrews, Jane M.
    INFLAMMATORY BOWEL DISEASES, 2023,
  • [36] Addendum to S3-Guidelines Crohn's disease and ulcerative Colitis: Care of Patients with Inflammatory Bowel Disease in the COVID-19 Pandemic - open Questions and Answers (vol 58, pg 672, 2020)
    Stallmach, A.
    Sturm, A.
    Blumenstein, I
    Aden, K.
    Andus, T.
    Atreya, R.
    Autschbach, F.
    Bachmann, O.
    Bettenworth, D.
    Boecker, U.
    Bokemeyer, B.
    Brechmann, T.
    Bufler, P.
    Buening, J.
    Daebritz, J.
    de Laffolie, J.
    Ehehalt, R.
    Esters, Ph
    Fellermann, K.
    Fichtner-Feigl, St
    Goetz, M.
    Gross, C.
    Hartmann, F.
    Hartmann, P.
    Haeuser, W.
    Herrlinger, K.
    Hoffmann, J. C.
    In der Smitten, S.
    Kaltz, B.
    Kanbach, L.
    Kannengiesser, K.
    Keller, K-M
    Kienle, P.
    Klaus, J.
    Kreis, M.
    Kroesen, A-J
    Kruis, W.
    Kuehbacher, T.
    Langhorst, J.
    Leifeld, L.
    Luegering, A.
    Maaser, Ch
    Matthes, H.
    Moog, G.
    Niess, J. H.
    Ockenga, J.
    Ott, C.
    Pace, A.
    Preiss, J.
    Reinshagen, M.
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2020, 58 (07): : e367 - e367
  • [37] Increased risk of developing Crohn's disease or ulcerative colitis in 17 018 patients while under treatment with anti-TNFα agents, particularly etanercept, for autoimmune diseases other than inflammatory bowel disease
    Korzenik, Joshua
    Larsen, Michael Due
    Nielsen, Jan
    Kjeldsen, Jens
    Norgard, Bente Mertz
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2019, 50 (03) : 289 - 294
  • [38] Aberrant responses to TLR (Toll-Like-Receptor) agonists and common luminal antigens (Ags) in patients with inflammatory bowel diseases (IBD); Difference between Crohn's disease (CD) and ulcerative colitis (UC)
    Jyonouchi, Harumi
    Monteiro, Iona M.
    Geng, Lee
    Cushing-Ruby, Agnes
    GASTROENTEROLOGY, 2007, 132 (04) : A223 - A223
  • [39] Commentary on Jaghult S, Saboonchi F, Johansson U, Wredling R and Kapraali M (2011) Identifying predictors of low health-related quality of life among patients with inflammatory bowel disease: comparison between Crohn's disease and ulcerative colitis with disease duration. Journal of Clinical Nursing 20, 1578-1587
    Purcell, Carol
    JOURNAL OF CLINICAL NURSING, 2013, 22 (17-18) : 2662 - 2663